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Abstract.  Platelet/endothelial cell adhesion molecule-1 
(PECAM-1,  CD31) is a member of the immunoglobu- 
lin superfamily present on platelets,  endothelial cells, 
and leukocytes that may function as a vascular cell 
adhesion molecule.  The purpose of this study was to 
examine the role of the cytoplasmic domain in 
PECAM-1  function.  To accomplish this,  wild-type and 
mutated forms of PECAM-1  cDNA were transfected 
into murine fibroblasts and the functional characteris- 
tics of the cells analyzed.  Wild-type PECAM-1  local- 
ized to the cell-cell borders of adjacently transfected 
cells and mediated heterophilic,  calcium-dependent 
L-cell aggregation that was inhibitable by a polyclonal 
and two monoclonal anti-PECAM-1  antibodies.  A  mu- 
tant protein lacking the entire cytoplasmic domain did 
not support aggregation or move to cell-cell borders. 
In contrast,  both forms of PECAM-1  with partially 
truncated cytoplasmic domains (missing either the 
COOH-terminal third or two thirds of the cytoplasmic 
domain) localized to cell-cell borders in 3T3  cells in a 
manner analogous to the distribution seen in cultured 
endothelial cells. L-cells expressing these mutants 
demonstrated homophilic, calcium-independent aggre- 
gation that was blocked by the polyclonal anti- 
PECAM-1  antibody, but not by the two bioactive 
monoclonal antibodies.  Although changes in the cyto- 
plasmic domain of other receptors have been shown to 
alter ligand-binding  affinity,  to our knowledge, 
PECAM-1  is the first example of a cell adhesion mole- 
cule where changes in the cytoplasmic domain result 
in a  switch in the basic mechanism of adhesion lead- 
ing to different ligand-binding  specificity. Variations in 
the cytoplasmic domain could thus be a potential 
mechanism for regulating PECAM-1  activity in vivo. 
p 
ECAM-1 (CD31) is a newly described 130-kD glyco- 
protein expressed on endothelial  cells, platelets,  and 
most leukocytes (Muller,  1992a;  Newman and  AI- 
belda,  1992;  DeLisser et al.,  1993b).  Although  the  full 
range of physiological  functions  of PECAM-1 have not yet 
been defined,  a number of lines of evidence indicate that it 
functions in the process of cell-cell adhesion.  On cultured 
endothelial  cells, PECAM-1  localizes  to cell-cell borders. 
Antibodies directed against PECAM-1 inhibit initial endothe- 
lial junction  formation  (Albelda et al.,  1990).  PECAM-1 
eDNA transfected into COS cells or 3T3 fibroblasts localizes 
exclusively at cell-cell borders of  adjacently transfected cells 
(Albelda et al.,  1991). PECAM-1  eDNA transfected  into 
mouse L-cells confers the ability to aggregate in a calcium- 
dependent,  heterophilic manner (Albelda et al., 1991; Muller 
et al.,  1992b;  DeLisser et al.,  1993a).  This categorization 
of PECAM-1 as a cell-adhesion  molecule is supported by ex- 
periments showing that it is involved in biological processes 
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such as cell migration  (Schimmenti et al., 1992), angiogene- 
sis (Merwin et al.,  1993),  leukocyte-endothelial  adhesion 
(Tanaka et al., 1992), and leukocyte transendothelial  migra- 
tion  (Muller et al.,  1993). 
Cloning studies have revealed that PECAM-1 is a member 
of the immunoglobulin  superfamily  (Ig-SF) (Newman et al., 
1990; Simmons et al., 1990; Stockinger et al., 1990; Zehn- 
der et al.,  1992) with homologies to other Ig-SF cell adhe- 
sion  molecules  such  as  VCAM-1, ICAM-1,  CEA, and 
NCAM. As such,  it contains six Ig-like homology units in 
its extracellular  domain,  a typical hydrophobic  transmem- 
brane  region,  and  a  cytoplasmic domain  containing  118 
amino acids (Newman et al.,  1990). A heparin-binding  se- 
quence on Ig-like domain 2 appears to be important in medi- 
ating  heterophilic  glycosaminoglycan-dependent  cell-cell 
adhesion (DeLisser et al.,  1993a). 
The function and behavior of many types of cell adhesion 
molecules including  integrins  (Mareantonio  et al.,  1990; 
Chan et al.,  1992; O'Toole et al.,  1991), selectins  (Kansas 
et al.,  1993), CD44 (Lesley et al.,  1992), as well as other 
members of the Ig-SF (Carp6n et al., 1992; Shin et al., 1991; 
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mains. The cytoplasmic region of PECAM-1 is also likely to 
play an important role in the function of the molecule. The 
ability of PECAM-1 to move to cell-cell borders suggests a 
requirement  for  cytoskeletai interaction  (Albelda  et  al., 
1991).  In  addition,  Newman  et  al.  (1992) have  found 
PECAM-1  associated  with  the  cytoskeleton of activated 
platelets. To date, however,  there is little understanding of 
how the structure of the cytoplasmic domain of PECAM-1 
contributes  to  the  functional properties  of the  molecule. 
Therefore, to examine the role of the cytoplasmic domain in 
PECAM-l-mediated intercellular adhesion, wild-type, and 
mutated forms of PECAM-I  cDNA were transfected into 
murine fibroblasts and the functional characteristics of the 
cells analyzed. Our results indicate that the cytoplasmic do- 
main  is  required  for  PECAM-1  to  localize  to  cell-cell 
borders and to support aggregation. Surprisingly, however, 
we also found that partial deletions of the cytoplasmic do- 
main markedly altered the functional characteristics of bind- 
ing, converting PECAM-l-mediated aggregation from a het- 
erophilic to homophilic process. These findings demonstrate 
that alterations in the cytoplasmic domain result in changes 
in the extraceUular region that affect the functional charac- 
teristics of PECAM-1 binding and suggest a potential mecha- 
nism for regulating PECAM-1  activity in diverse biological 
processes. 
Materials and Methods 
Construction of PECAM-1 Mutant cDNAs 
PECAM-1 mutants (Fig. 1) were constructed by manipulation of wild-type 
PECAM-1 eDNA that had been subcloned into the pESP-SVTEXP expres- 
sion vector (designated "TEX/PECAM") as previously described (Albelda 
et al.,  1991). 
Cytoplasmic Deletion Mutant-1 (CDM1) and Cytoplasmic Deletion 
Mutant-2 (CDM2). To prepare constructs missing approximately the termi- 
nal third of the cytoplasmic domain (CDM1) and the terminal two thirds of 
the cytoplasmic domain (CDM2), we took advantage of a unique Bgl II site 
present at bp 2247 and a unique Tthlll I site at bp 2143  (Fig. 1 A). Wild- 
type TEX/PECAM was reacted with the appropriate restriction enzyme. 
The linearized plasmids were then treated with mung bean nuclease to make 
the ends blunt and ligated to a synthetic multiple reading frame termination 
linker (SMURFT-Pharmacia LKB Biotechnology, Piscataway,  NJ). Bacte- 
ria were transformed with the ligation mixture and plasmid DNA isolated. 
Since this linker also contains an Xba I site, we were able to confirm the 
presence of  the linker by the presence  of  this site. Constructs with the appro- 
priate restriction digest pattern were then sequenced to confirm that the ap- 
propriate stop codon had been inserted. 
Cytoplasmic Deletion Mutant-3 (CDM3). To prepare a construct miss- 
ing the entire cytoplasmic domain, a modification of  the PCR was used, tak- 
ing advantage of the fact that additional nucleotide sequences can be added 
to the 5' end of PCR primers without affecting the ability of the reaction 
to amplify these sequences. 
The full length TEX/PECAM was cut with the restriction enzymes Nhe 
I and Asu lI (Fig. 1 A). Each of these enzymes has a unique restriction site. 
The Nhe I site is at bp 1825 and the Asu II site is in the 3' linker sequence. 
The larger 6.0-kb fragment, containing the vector plus the eDNA coding 
for most of the extraceUular domain was purified using low-melt agarose. 
A 5' PCR primer identical to the coding strand of PECAM-1 from nucleo- 
tides 1820 to 1834 was synthesized. This region, near the transmembrane 
domain, contains the unique Nhe I restriction site. A 3' PCR primer was 
constructed to contain 17 bp complementary to the terminal portion of the 
transmembrane domain (bp 2003-1986).  The 5' portion of this primer was 
designed to contain an "in frame" stop codon, a unique Aoc I restriction 
site as well as an Asu II restriction site. These primers were used to generate 
a 200-bp fragment that was purified, reacted with the restriction enzymes 
Nhe I and Asu II, and repurified. The digested PCR fragment was then 
ligated to the previously digested vector and the resultant DNA mixture 
used for transformation. Plasmid DNA was isolated from the resultant colo- 
nies and the appropriate DNA, as identified by the presence of a new Aoc 
I site, was sequenced. 
Transfection of  Mutant cDNAs 
Purified eDNA was cotransfected  with a neomycin resistance gene into COS 
cells and 3T3 cells using calcium phosphate as described previously (AI- 
belda et al.,  1991). 3T3 cell lines expressing high levels of the PECAM-I 
cDNAs were selected using G418 (Gencticin, GIBCO BRL, Gaithersburg, 
MD) followed by subcloning. 
Unlike our success with 3T3 cells, we were unable to reliably obtain sta- 
ble lines expressing high levels of PECAM-1 in mouse L-cells using the 
pESP-SVTEXP expression vector. We therefore subcloned the constructs 
into the pcDNAI/Neo vector (Invitrogen, San Diego,  CA)  followed by 
transfection into L-cells and selection and subcloning in G418 as previously 
described (Albelda et al.,  1991). 
Antibodies 
The  following anti-PECAM-1  monoclonal antibodies were used: mAbs 
PECAM-I.I, PECAM-I.2, and PECAM-I.3, (provided  by Dr. Peter  New- 
man, Blood Center  of  Southeastern  Wisconsin, Milwaukee, WI) generated 
by immunizing mice with PECAM-I purified  from human platelets  (New- 
man et  al.,  1992;  Albelda  et  al.,  1991);  mAb hec7  (provided  by  Dr.  William 
Muller,  Rockefeller  University,  New York,  NY) (Muller  et  al.,  1989);  mAb 
HDO3 (provided  by  Dr.  Stephen  Shaw, National  Cancer  Institute,  Bethesda, 
MD), and  mAb 4G6 generated  in  mice  after  immunization with  PECAM-I- 
transfected  3"1"3  cells.  Each of these antibodies  immunoprecipitated the 
characteristic  130-kD protein  from human umbilical  vein  endothelial  cells 
and selectively  recognized  3"I"3  ceils  transfected  with PECAM-I. 
Immunofluorescent Staining 
Transfected  3T3  cell  lines  expressing  wild-type and  mutant  forms  of 
PECAM-1 in >90% of cells were plated at 4  ×  104 cells/era  ~ on glass cov- 
erslips coated with 1% gelatin in PBS (Difco Labs., Detroit, MI). After the 
cells had grown to confluence, cells were fixed with 3 % paraformaldehyde 
for 20 rain, and then permeabilized with ice-cold 0.5% NP-40 for 1 rain. 
After extensive washing, anti-PECAM-1 mAb 4G6 was added for 1 h. After 
rinsing, the coverslips were stained with a  1:200 dilution of FITC-labeled 
anti-mouse antibody (CappeU,  West Chester,  PA)  for  1 h.  Ceils were 
viewed on a Zeiss phase-epifluorescent  microscope using a 63× planapochro- 
mat oil-immersion lens numerical aperture  1.4 and photographed using 
TMAX film at 3200 ASA. 
Fluorescence-activated Cell Sorting Analysis 
L-cells transfected with wild-type or mutant PECAM-1 cDNAs were enzy- 
matically removed for T25 flasks with trypsin/EDTA, washed in medium 
containing 10% FBS, and treated with various anti-PECAM-1 mAbs for 1 h 
at 40C,  The primary antibody was then removed, the cells washed twice 
with ice-cold PBS, and a  1:200 dilution of FITC-labeled goat anti-mouse 
secondary antibody (Cappell) added for 30 rain at 4°C. After washing in 
cold PBS, flow cytometry was performed using a Cytofluorograph 50H cell 
sorter equipped with a  2150  data handling system (Ortho Instruments, 
Westwood, MA). 
Cell Labeling 
To  metabolically label cellular proteins,  confluent "I"25 flasks  were  in- 
cubated in medium containing 100 ~Ci [3SS]methionine  for 18 h as previ- 
ously described (Albelda et al.,  1990). 
For 32Pqabeling,  confluent monolayers of L-cell transfectants in six well 
plates were incubated at 37°C in phosphate-free RPMI with 5% dialyzed 
FCS for 18 h. After the monolayers were washed twice with PBS, the cells 
were then incubated for 4 h with phosphate-free RPMI with 10% dialyzed 
serum and 250 t~Ci/ml sodium ortho[32P]  phosphate (Amersham Corp., 
Arlington Heights, IL).  After incubation,  the monolayers were washed 
twice with cold PBS and the membrane proteins extracted by adding 300 
~1 of TNC (0.01 M Tris acetate, pH 8.0, 0.5 % NP-40 and 0.05 mid CaC12) 
containing 2 mM PMSF and 10 mM sodium orthovanadate to the wells on 
ice for 20 min. The resulting extracts were then used immediately or stored 
at  -20°C until use. 
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Nonionic detergent extracts  were  preadsorbed for 30 min at 40C  with 
protein-A-conjugated Sepharose beads (Pharmacia Fine Chemicals). After 
removal of the beads, the appropriate antibody was added to the precleared 
supernatants, together with fresh protein A-Sepharose beads for 1 h at 4°C. 
After the immunoprecipitation, the beads were washed five times with 50 
mM Tris HC1 (pH 7.5), 150 mM NaCI,  I% Triton X-100, 5% deoxycholate, 
and 0.1% SDS. The sample was then dissolved with electrophoresis loading 
buffer (62.5  mM "Iris base, 2% SDS,  10% glycerol,  pH 6.8), electropho- 
resed on 6 % polyacrylamide gels, and processed for autoradiography using 
Kodak XR-5 X-ray film at -700C. 
Aggregation of  L-Cell Transfectants 
The aggregation assay used in these studies has been described in detail pre- 
viously (Albelda et al., 1991; Muller et al., 1992b; DeLisser et al., 1993a). 
Briefly,  stable L-cell transfectants,  which had been plated (840  x  106 
cells/75-cm  2 flask) and grown overnight, were removed from the flasks by 
treating the cells with low dose trypsin/EDTA for 3 rain. Fluorescence- 
activated cell sorting (FACS)  l analysis using various anti-PECAM-I  antibod- 
ies, demonstrated that PECAM-1 was not altered by this treatment (data not 
shown).  The cells were washed twice with 10 mM EDTA in PBS, pH 7.2, 
and twice with HBSS  without divalent cations.  Cells were finally  resus- 
pended to a  concentration of 'x,106/ml in HBSS  with or without 1 mM 
Ca  +2. Heparin (sodium salt, from porcine intestinal mucosa; Sigma Chem. 
Co., St.  Louis, MO) and antibodies were added as indicated  to give the 
desired concentration. After the cells had been dispersed to a single cell 
suspension, 1-ml aliquots were transferred to wells in a 24-well non-tissue 
culture plastic tray (Costar Corp., Cambridge, MA) that had been previ- 
ously incubated 2 % BSA in HBSS for at least 1 h and washed thoroughly 
with HBSS immediately before use to prevent nonspecific binding to the tis- 
sue culture dish.  The non-tissue culture trays  containing the suspended 
L-cells were rotated on a gyratory platform (100 rpm) at 37°C for 45 min. 
Aggregation was quantified  by examining  representative aliquots  from 
each sample on a  hemacytometer grid using phase contrast optics.  The 
number of single cells (cells in aggregates <3) remaining versus those pres- 
ent in aggregates of greater than three cells were counted from four 1-mm 
squares.  At least 600 cells were counted from each sample.  Data were ex- 
pressed as the percent of total cells present in aggregates. 
Mixed Aggregation Assay 
To determine whether the PECAM-1  dependent L-cell aggregation  was 
mediated by homophilic or heterophilic mechanisms, =mixed aggregation" 
assays were performed (Muller et al.,  1992b; DeLisser et al.,  1993a).  In 
these  experiments,  L-cell  aggregation  was  performed  by  mixing  non- 
transfected and transfected cells, with one of the two cell types fluorescentty 
labeled before mixing. After the cell line designated for labeling had been 
washed once with EDTA,  it was resuspended in HBSS to a total volume 
of one ml. One ml of rhodamine-conjugated dye solution at a final concen- 
tration of  1 /zM  (Sigma  Immunochemicals, St.  Louis,  MO),  in buffer 
provided by the manufacturer,  was added, followed by incubation at room 
temperature for 5-10 min. Labeling was terminated by adding an equal vol- 
ume FBS and by washing the cells with HBSS. The second EDTA wash and 
the two HBSS washes were then completed as previously described. Each 
set of cells, one labeled, and the other unlabeled, were resuspended at 106 
cells/ml. Aliquots of 0.5 ml were combined in the wells of a 24-well non- 
tissue culture plate and allowed to aggregate as described above. After the 
aggregation  was completed, the cells were viewed under epifluorescence. 
The number of fluorescent  cells in each aggregate  of a  given size  was 
counted. Quantitative analysis of the aggregating cell populations was per- 
formed as described by Sieber and Roseman (1981). 
Results 
Construction and Characterization of 
Mutated Forms of PECAM-1 Lacking Regions of the 
Cytoplasmic Domain 
To study the function of the cytoplasmic domain, three trun- 
1.  Abbreviation  used  in  this  paper:  FACS, fluorescence-activated  cell 
sorting. 
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Figure 1.  Construction of PECAM-1 cytoplasmic domain deletion 
mutants. (A) A schematic representation of the cDNA sequence for 
the 6th Ig-like unit and the transmembrane and cytoplasmic do- 
mains of PECAM-1 in the expression vector pESP-SVTEXP.  The 
solid bar represents the 6th Ig-like domain. The open bar represents 
the transmembrane region.  The hatched bar represents the cyto- 
plasmic  domain.  Stop  codons  were  inserted at two  convenient, 
unique  restriction enzyme  sites,  Bgl  II  and  Tthlll  I  to  create, 
respectively,  the  mutants  CDM1  and  CDM2.  CDM3  was  con- 
structed by digesting the wild-type PECAM-1  eDNA with Nhe I 
and Asu II restriction enzymes (to remove the sequence coding the 
cytoplasmic domain), followed by the ligation of a PCR-generated 
fragment into the digested vector to reconstitute the sequence for 
the transmembrane domain. (B) Wild-type and the three cytoplas- 
mic domain deletion mutants. The terminal third of the cytoplasmic 
domain is deleted from CDM1; the terminal two thirds of the cyto- 
plasmic domain is missing from CDM2; and the entire cytoplasmic 
domain is absent from CDM3. 
cated  forms of PECAM-1  were created by inserting  stop 
codons at specific locations in the coding sequence of the cy- 
toplasmic  domain  of wild-type  PECAM-1  as  outlined  in 
the  methods  (see  Fig.  1).  Cytoplasmic deletion mutant-1 
(CDM1)  was  truncated at amino  acid  676  and  contained 
about 2/3 of the cytoplasmic domain. Cytoplasmic deletion 
mutant-2 (CDM2) was truncated at amino acid 641 and con- 
tained about 1/3 of  the cytoplasmic domain. Cytoplasmic de- 
letion mutant-3 (CDM3) was truncated at amino acid 593, 
immediately after the  transmembrane  region  (Fig.  1 B). 
Each mutant construct was confirmed by sequencing. These 
constructs, along with wild-type PECAM-1 eDNA were sub- 
sequently transfected into mouse 3T3 cells and L-cells for 
anaiysis. Fig. 2 A illustrates the relative sizes of each of the 
PECAM-1  constructs.  Transfected L-cells were metaboli- 
cally labeled with psS]methionine and immunoprecipitated 
with an anti-PECAM-1 monoclonal antibody that did not re- 
act with non-transfected cells (data not shown). Each of the 
truncation mutants was of  the appropriately smaller size than 
the wild-type molecule. 
Previous studies have demonstrated that the cytoplasmic 
domain of PECAM-1  is  constitutively phosphorylated on 
serine and threonine residues (Newman et al.,  1992; Zehn- 
der et al.,  1992).  To determine if these Constructs main- 
tained the ability to be phosphorylated, L-cells containing 
each of the PECAM-1 constructs were incubated in radiola- 
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PECAMq expressed in L-ceU  transfectants. (A) Transfected L-cells 
were metabolically labeled with [35S]methionine  and immunopre- 
cipitated with anti-PECAM-1 monoclonal antibody. The size of the 
mutant constructs varied from 95 to 120 kD. (B) L-cell transfec- 
tants were labeled with ortho [32p]phosphate, extracted with non- 
ionic detergent in the presence of sodium vanadate and immunopre- 
cipitated  with  anti-PECAM-1 monoclonal  antibody. Wild-type, 
CDM1, and CDM2 demonstrated similar levels of constitutive lev- 
els of phosphorylation.  As expected, CDM3 was not phosphor- 
ylated. Numbers on the right represent molecular weight markers 
in kilodaltons. 
bel~ sodium orthophosphate for 4 h, extracted in non-ionic 
detergent in the presence of sodium vanadate, and immuno- 
precipitated with anti-PECAM-1 monoclonal antibody. Du- 
plicate  wells  were labeled  with  [35S]methionine  and  pro- 
cessed identically (Fig. 2 A). As shown in Fig. 2 B, wild-type 
PECAM-1 in L-cells was constitutively phosphorylated (lane 
/). As expected, the CDM3 mutation lacking the cytoplas- 
mic domain was not labeled (lane 4), even though these cells 
were synthesizing the truncated protein (Fig. 2 A, lane 4). 
Both CDM1 and CDM2,  however, were clearly labeled by 
p2p] at levels similar to wild type. 
The Cytoplasmic Domain Is Required  for PECAM-1 
Localization to Cell-CeU Borders 
After  transfection  into  Cos-7  and  3T3  ceils,  wild-type 
PECAM-1  localizes to cell-cell borders of adjacent trans- 
Figure 3. Localization of wild-type and mutant PECAM-1 on 3T3 
ceils. 3T3 clones expressing wild-type and each cytoplasmic dele- 
tion construct were plated onto glass coverslips, allowed to grow 
to near confluence, fixed and stained with an anti-PECAM-1 mAb 
followed by a secondary FITC-labeled anti-mouse antibody. Wild- 
type PECAM-I (A), as well as CDM1 (B) and CDM2 (C), concen- 
trated at intercellular borders (arrows). CDM3 (D) demonstrated 
little tendency to localize at cell-cell contacts (arrowheads). 
fected ceils in a manner analogous to the distribution seen 
in cultured endothelial cells (Albelda et al.,  1991). The re- 
quirement of  the cytoplasmic domain for PECAM-1 intercel- 
lular localization was  determined by immunofluorescence 
analysis of 3T3 clones expressing each truncated form of 
PECAM-1  (Fig.  3).  Fig.  3  A  shows  wild-type PECAM-1 
localized to cell-cell borders, as expected (Albelda et al., 
1991). In contrast, the construct missing the entire cytoplas- 
mic domain (CDM3),  showed only a minimal tendency to 
localize at cell-cell contact sites (Fig. 3 D). Although some- 
what  difficult to  quantitate,  cells  transfected  with  either 
CDM1 (Fig. 3 B) or CDM2 (Fig. 3 C) retained their ability 
to move to cell-cell borders. 
Deletions of the Cytoplasmic Domain Alter the 
Binding Characteristics of  PECAM-1 
When transfected into murine L-cell fibroblasts, wild-type 
PECAM-1  mediates calcium- and glycosaminoglycan-depen- 
dent, heterophilic aggregation (Albelda et al.,  1991; Muller 
et al., 1992b; DeLisser et al., 1993a). Therefore, each cyto- 
plasmic deletion mutant was subcloned into the pcDNAI- 
Nco vector and transfected into L-cells. After selection in 
G418, clones were isolated, and levels of PECAM-1 expres- 
sion on the cell surface were determined by FACS analysis 
(Fig. 4).  Each clone expressed PECAM-1  on greater than 
90% of the cells at similar fluorescence intensities. Multiple 
independent clones of each mutant expressing high levels of 
protein were chosen for further study. 
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transfectants.  Cell  surface expression  of L-cells  transfected with 
wild-type PECAM-I, CDM1, CDM2, and CDM3 constructs were 
assessed  by  fluorescence-activated  cell  sorting  using  an  anti- 
PECAM-I  polyclonal antibody (A, B, C, and D). For each L-cell 
transfectant,  >90% of the cells were positive. 
Each construct was tested for its ability to support L-cell 
aggregation in the presence and absence of calcium (Fig. 5). 
In Fig. 5 A, as expected, wild-type PECAM-1 demonstrated 
calcium-dependent aggregation. Sham transfectants demon- 
strated minimal aggregation in the presence or absence of 
calcium (see Albelda et al.,  1991).  In contrast, the CDM3 
construct that was lacking the entire cytoplasmic domain, 
was unable to support L-cell aggregation in either the pres- 
ence or absence of calcium. Although removal of the entire 
cytoplasmic  domain  completely  eliminated  the  ability  of 
PECAM-1 to support aggregation, deletions of specific por- 
tions of the cytoplasmic domain led to surprising alterations 
in the adhesive properties of the PECAM-1 molecule (Fig. 
5). Cells transfected with constructs lacking either the termi- 
nal one third of the cytoplasmic domain (CDM1) or the ter- 
minal two thirds  of the  cytoplasmic domain  (CDM2)  ag- 
gregated equally well in both the presence and absence of 
calcium (Fig. 5 A). In both cases, even though the cells ex- 
pressed  comparable  levels of PECAM-1  on  their  surface 
(Fig. 4), the cells expressing truncated forms of the molecule 
consistently displayed higher levels of aggregation than cells 
transfected with wild-type PECAM-1. 
The  effects of temperature  and  heparin  on  mutant  and 
wild-type aggregation in the presence of calcium were also 
studied.  As shown in Fig. 5 B, cells transfected with either 
CDM1  or CDM2, like wild-type transfectants were unable 
to aggregate at low temperatures suggesting that this process 
requires metabolic energy (see also Muller et al.,  1992b). 
Heparin (50 #g/ml) blocked the aggregation mediated by the 
wild-type PECAM-1, as previously demonstrated (DeLisser 
et al.,  1993a).  In contrast, it did not significantly affect the 
aggregation mediated by CDM1 or CDM2 (Fig. 5 C), even 
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Figure 5. Aggregation of wild-type and mutant PECAM-1 express- 
ing L-cell transfeetants.  The aggregation assay using L-cell trans- 
fectants was performed as described in Materials and Methods. (A) 
Calcium dependence. Wild-type and mutant transfected L-cell were 
allowed to aggregate in the absence or presence ofl mM calcium. 
Wild-type  transfectants  demonstrated  calcium-dependent  aggre- 
gation  while  CDM1 and  CDM2  displayed calcium-independent 
aggregation.  CDM3  did not  aggregate.  Subsequent  experiments 
were performed to study the effect of temperature  and heparin on 
the aggregation of wild-type,  CDM1, and CDM2 in the presence 
of calcium. (B) Effect of lowering temperature.  Lowering the tem- 
perature to 4°C blocked the aggregation of all three constructs. (C) 
Effect of heparin.  Heparin (50 #g/ml) inhibited the aggregation of 
wild-type,  but  not CDM1-  or  CDM2-expressing  cells.  Similar 
results were seen at concentrations up to 500 #g/ml. For CDM1 and 
CDM2, similar results were obtained  for experiments performed 
in the absence of calcium. The data presented are representative of 
at least three experiments done in duplicate and of at least two inde- 
pendent  clones. 
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Figure 6. Effect of Anti-PECAM-1 antibodies on the aggregation of 
wild-type and mutant PECAM-1 L-cell transfectants. One poly- 
clonal and six monoclonal (4G6, PECAM-I.1 [1.1], PECAM-L2 
[1.2], PECAM-1.3 [1.3], bee7, HD03) were studied for their effect 
on the aggregation process in the presence of calcium (A, B, and 
C). The polycloual antibody was able to block the aggregation of 
all three constructs. Two monoclonal antibodies (mAb 4G6 and 
mAb PECAM-1.2) inhibited wild-type dependent aggregation (A) 
but had no effect on the aggregation mediated by CDM1 (B) or 
CDM2 (C). The data presented are representative of at least two 
experiments done in duplicate.  For CDM1 and CDM2,  similar 
results were obtained for experiments performed in the absence of 
calcium. 
Two Monoclonal Antibodies Block Vvild 7)2pe- But Not 
CDM1- or CDM2-dependent Aggregation 
Since aggregation mediated by wild-type PECAM-1 can be 
inhibited  by  a  polyclonal antibody  made  against  platelet 
PECAM-1 (Fig. 6 A; see also Albelda et al., 1991), the abil- 
ity of this antibody to block CDM1- and CDM2-mediated 
aggregation was also tested. As shown in Fig. 6, B and C, 
the polyclonal antibody was able to inhibit the aggregation 
induced by the mutant PECAM-1 forms, confirming that the 
interaction was specific and PECAM-1  dependent. 
To further explore the nature of the binding mediated by 
the different forms of PECAM-1, we tested a panel of mono- 
clonal antibodies for their ability to inhibit aggregation. Six 
mAbs were screened. All recognized wild-type PECAM-1 
and each of  the mutant forms on FACS analysis and by immu- 
noprecipitation (data not shown). When tested with L-cells 
transfected with wild-type PECAM-1, two of the six mAbs 
(PECAM-1.2 and 4G6) were able to inhibit aggregation (Fig. 
6 A). In contrast, when these same antibodies were used in 
aggregation assays using cells transfected with CDM1  and 
CDM2, no inhibition was observed (Fig. 6, B and C). The 
failure to block aggregation was not due to a loss in the abil- 
ity of the antibodies to bind to the mutant proteins since all 
demonstrated roughly equivalent binding on FACS analysis 
(Table I).  Similar results were obtained with experiments 
performed in the absence of calcium. Three of the antibodies 
(hec7, PECAM-1.3 and HDO3) appeared to induce aggrega- 
tion.  However,  this  effect was  probably  due  to  antibody 
cross-linking of PECAM-1, as Fab fragments of these anti- 
bodies  failed  to  enhance  aggregation  (data  not  shown). 
These results indicate that the binding observed in the cells 
transfected with the altered PECAM-1 constructs use differ- 
ent epitopes from those used in the wild-type PECAM-1. 
CDM1 and CDM2 Mediate Homophilic Aggregation 
The experiments described above suggested that the aggrega- 
tion mediated by the mutant constructs was fundamentally 
different than that of the wild-type PECAM-1 molecule. To 
determine if the ligand-binding specificity (i.e., heterophilic 
vs homophilic) was different, a mixed aggregation assay was 
used (Muller et al., 1992b: DeLisser et al., 1993a). In these 
Table I. FACS Analysis of WiM-Type and Mutant PECAM-1 
L-cell Transfectants  Using Anti-PECAM-1  Polyclonal  and 
4G6 and PECAM-1.2 Monoclonal  Antibodies 
Mean fluorescence intensity 
Irrelevant  Polyclonal 
Cell type  control mAb  antibody  mAb 4G6  mAb  1.2 
Wild-type  35  136  97  97 
CDM1  37  139  96  112 
CDM2  40  138  103  118 
CDM3  38  141  92  88 
The ability of an irrelevant  control  mAb,  a polyclonal  anti-PECAM-1  anti- 
body, and two blocking monoclonal antibodies (4G6 and PECAM-1.2) to bind 
to L-cells expressing wild-type PECAM-I and mutant constructs was assessed 
by fluorescence-activated cell sorting analysis. The mean (log) fluorescence in- 
tensity for each antibody was determined for each cell type. The polyclonal an- 
tibody, mAb 4G6 and mAb PECAM- 1.2 bind equally well to wild-type and the 
mutant constructs.  Similar results were noted for the other four non-blocking 
monoclonal antibodies. 
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transfected with PECAM-1 were allowed to aggregate in the  3o 1 Wild Type 
presence of calcium, after fluorescent labeling of one of the  t  cell lines. After 45 min,  the composition of aggregates of 
specific sizes were determined and a frequency distribution  ~  . 
•  ~  20  tabulated. As reported in detail previously (DeLisser et al., 
1993a), and shown in Fig. 7 A, the presence of transfected 
and non-transfected cells in the majority of the aggregates is 
characteristic of heterophilic aggregation. That is, PECAM-1  ~  l0 
on one cell is interacting with a non-PECAM-1 ligand.  In  d~ 
marked  contrast,  the  pattern  of aggregation  for both  the  ~ 
CDM1 (Fig. 7 B) and CDM2 (Fig. 7 C) transfected cells was  z  llll  characterized by  aggregates  composed almost entirely of  0  s/0  ~t 
transfected  cells,  resulting  in  distribution  curves  shifted 
markedly to the right. This pattern is characteristic of homo- 
philic aggregation (PECAM-1  on one cell interacting with 
PECAM-1 on an adjacent cell) and has been observed previ-  B 
ously for cadherins (Jaffe et ai., 1990; Muller et al., 1992b).  s0- 
Similar results were obtained for 4- and 6-cell aggregates  1 CDMI 
and  when experiments were conducted in  the absence of 
calcium. 
Discussion 
The purpose of  this study was to evaluate the role of the cyto- 
plasmic domain in PECAM-1 function. To accomplish this, 
full length and truncated versions of PECAM-1 cDNA were 
transfected into murine fibroblasts and their ability to pro- 
mote cell-cell adhesion was analyzed. Wild-type PECAM-1 
accumulated at cell-cell borders in transfected 3T3 cells and 
supported  L-cell  aggregation  in  a  heterophilic,  calcium- 
dependent manner that was inhibitable by heparin. Aggrega- 
tion was  blocked by a  polyclonal anti-PECAM-1  antibody 
and two specific monoclonai antibodies. A  PECAM-1  mu- 
tant with  a  complete deletion of the cytoplasmic domain 
showed minimal  localization to adjacent cell-cell borders 
and did not promote L-cell aggregation. In marked contrast, 
two mutants with partial deletions of their cytoplasmic do- 
mains displayed markedly altered adhesion properties. Both 
truncated proteins retained the ability to move to cell-cell 
borders; however, the CDM1 mutant (lacking the carboxyl- 
terminal  one  third  of the  cytoplasmic  domain)  and  the 
CDM2 mutant (lacking the carboxyl-terminai two thirds of 
the cytoplasmic domain)  supported homophilic,  calcium-, 
and heparin-independent aggregation. Although aggregation 
was still blocked by the polyclonal anti-PECAM-1 antibody, 
the monoclonal antibodies that inhibited heterophilic bind- 
ing had no effect on homophilic aggregation mediated by ei- 
ther truncated form of PECAM-1,  despite their ability to 
bind to the mutated PECAM-1  molecules as demonstrated 
by FACS. 
Truncation of the cytoplasmic domain has been shown to 
affect the function of a number of cell adhesion molecules, 
including integrins,  selectins, CD44,  and immunoglobulin 
superfamily members. In most cases, deletions of the cyto- 
plasmic domain have changed the ability of receptors to in- 
teract with elements of the cytoskeletai complex (Solowska 
et al., 1989; Hayashi et al., 1990; Marcantonio et al., 1990; 
Nagafuchi  and  Takeichi,  1988;  Lesley et al.,  1992).  Al- 
though O'Toole et ai. (1991) have presented data to show that 
deletion  of the  cytoplasmic  domain  of the  integrin  o,  ro 
subunit could lead to an increase in the affinity of the Otnb~3 
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Figure 7.  Mixed aggregation studies. Mixed aggregation assays 
were performed in which equal numbers of non-transfected and 
transfected L-cells were mixed together after fluorescent labeling 
of  one of  the cell lines. After incubation, the number of  labeled cells 
within each 5 cell aggregate was counted. The data is representative 
of at least three experiments. (,4)  When wild-type PECAM-1 L-cell 
transfectants were mixed with non-transfected L-cells the majority 
of aggregates were made up of mixtures of transfected and non- 
transfected cells. A "normal" distribution is noted, indicative of a 
heterophilic interaction (see DeLisser et al., 1993a). Similar mixed 
aggregation experiments with CDM1 (B) and CDM2 (C) yielded 
aggregates that were composed primarily of transfected cells. The 
frequency distribution  is  shifted  toward the  right,  reflecting a 
homophilic interaction. 
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change in the nature of the adhesion process accompanying 
partial deletion of the cytoplasmic domain of PECAM-1.  To 
our knowledge, this is the first example in which alterations 
in the cytoplasmic domain result in changes in ligand spec- 
ificity as well as cation dependence. 
How might these alterations in the cytoplasmic domain of 
PECAM-1 lead to changes in the functional properties of the 
molecule? Although we currently have no clear answer to 
this question, data involving other adhesion molecules sug- 
gest a number of possibilities. Deletions in the cytoplasmic 
domain could cause changes inahe overall folding of  the mol- 
ecule resulting in a change in the conformation of the ex- 
tracellular portion of the molecule. The altered conforma- 
tion  would  present  different ligand-binding domains  and 
therefore have altered divalent cation requirements. It is also 
possible  that the  changes  in  the  extracellular region  are 
related to an altered pattern of phosphorylation of the cyto- 
plasmic domain in the mutants. The function of a number of 
adhesion molecules, such as the f12 integrins, are known to 
be affected by the state of cytoplasmic phosphorylation. For 
example, phosphorylation of LFA-1 by both protein kinase 
C-dependent and independent pathways regulate the binding 
affinity of this molecule for ICAM-1  (Hibbs et al.,  1991; 
Hedman and Lundgren, 1992). There is circumstantial evi- 
dence to suggest that the phosphorylation state of PECAM-I 
may be important in function. Increases in baseline levels of 
phosphorylation have been observed after activation of en- 
dothelial cells, platelets, and lymphocytes, and appear to in- 
volve exclusively phosphorylation of serine residues in the 
cytoplasmic domain (Newman et al., 1992; Zehnder et al., 
1992).  Although there do not appear to be any gross differ- 
ences in the level of phosphorylation between the wild-type 
PECAM-1 versus the CDM1 or CDM2 mutants (Fig. 2 B), 
our results do not exclude the possibility that one or more 
of  the serine residues in the proximal third of the cytoplasmic 
domain ($611,  $620,  $626, $634), common to both CDM1 
and CDM2, may be differentially phosphorylated. 
Another mechanism by which alterations in the cytoplas- 
mic domain could affect PECAM-1  function might involve 
changes in the interaction of the truncated molecules with 
other cellular proteins. Cytoplasmic domain-cytoskeletal  in- 
teractions have been shown to be important for a number of 
cell  adhesion  molecules  (Nagafuchi and Takeichi, 1988; 
Otey et al., 1990; Burridge et al., 1988; Lacy and Underhill, 
1987; Kansas et al.,  1993) and have recently been demon- 
strated for platelet PECAM-1  (Newman et al.,  1992).  It is 
possible that the altered ability to interact with cytoskeletal 
structures could change the nature of PECAM-1 binding. Al- 
ternatively, the truncated mutants may have also lost the abil- 
ity to associate with some, as yet unidentified, PECAM-1- 
associated proteins, analogous to molecules such as integrin 
modulating factor-1  (Hermanowski-Vosatka  et al.,  1992) or 
integrin-associated protein (Brown et al.,  1990). 
Whatever the mechanism, it appears that truncation of the 
PECAM-I  cytoplasmic domain leads to alterations in the 
conformation of the extracellular portion of the molecule as 
evidenced not 0nly by altered dependence upon divalent cat- 
ions and glycosaminoglycans,  but also by the fact that mono- 
clonal antibodies that block cell-cell aggregation mediated 
by intact PECAM-1 no longer block aggregation, despite be- 
ing able to bind to the mutant PECAM-1  molecules (Table 
I). Interestingly, the epitopes of these mAbs that block het- 
erophilic aggregation, 4G6 and PECAM-1.2, map to domain 
6 (Yan, H. C., H. M. DeLisser, and S. M. Albelda, manu- 
script in preparation) and are thus distinct from the heparin- 
binding sequence in domain 2. It is currently unclear how 
this region in loop 6 regulates heterophilic binding. 
Although the deletions created in the cytoplasmic domain 
described in this study were artificially engineered, there is 
intriguing evidence to suggest that naturally occurring alter- 
ations in the cytoplasmic domain of PECAM-1 (i.e., alterna- 
tive splicing) exist. Preliminary work (Kirschbaum, N. E., 
and P. J. Newman.  1993. Thromb. Haemostasis.  69:1010a) 
indicates that the gene for PECAM-1 is complex, containing 
16 exons and extending over more than 75 kilobases of DNA. 
The transmembrane and cytoplasmic domain are encoded by 
a  series  of short  exons  (exons  9-16).  Interestingly, these 
authors  reported  the  isolation of an  alternatively spliced 
cDNA clone missing 63 basepairs from the coding sequence 
for the cytoplasmic tail. The missing region corresponded 
exactly to exon 13 of the gene, a region of the molecule that 
is disrupted in our mutants (Newman, P. J., personal com- 
munication).  Since  alternative  splicing  may  represent  a 
means of etliciently changing the functional characteristics 
of a given protein (Smith et al., 1989), it is tempting to spec- 
ulate that changes in the cytoplasmic domain of PECAM-1 
generated  by  alternative  splicing,  might  play  a  role  in 
modulating the ligand interactions of PECAM-1  during vas- 
cular development or pathological conditions involving an- 
giogenesis or leukocyte-endothelial interactions. 
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